BioPorto A/S held its Annual General Meeting today as per the notice to convene the general meeting of March 18, 2015.
The shareholders approved the report on the Company’s activities and adopted the Annual Report 2014. Also, the Annual General Meeting adopted the proposed profit/loss allocation, and discharge was given to the Board of Directors and the Management Board. Furthermore, the remuneration of the Board of Directors was approved.
Thomas Magnussen, Torben A. Nielsen and Roar Bjørk Seeger offered themselves for re-election and were re-elected. In addition, Jan Kuhlmann Andersen was elected as a new board member.
Immediately after the Annual General Meeting, the Board of Directors elected Thomas Magnussen as its chairman and Torben A. Nielsen as its vice chairman.
PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab was re-elected as the Company’s auditor.
Please find attached the chairman’s report on the Company’s activities during the past year.
Gentofte, April 10, 2015
BioPorto A/S
The Board of Directors
Further information:
Gry Husby Larsen, Legal Counsel
Tel. no. (+45) 45 29 00 00, e-mail investor@bioporto.com
The kidney biomarker NGAL
Every year about 13 million people are struck by acute kidney injury worldwide, of whom about 4 million die. Nevertheless, there has been no real progress in methods of diagnosing kidney injury over the last half century. Existing methods, such as serum creatinine determination, only signal kidney failure 24-72 hours after the injury has taken place. In contrast, NGAL rises to diagnostic levels within a few hours of kidney injury and thus enables the physician to make vital clinical decisions before the damage progresses to potentially fatal renal shutdown. In addition to helping the patient, cost-benefit analyses show that implementing NGAL testing will contribute to reducing hospital costs in the management of kidney injury and its consequences.
About BioPorto
BioPorto Diagnostics A/S is an in-vitro diagnostics company that provides healthcare professionals in clinical and research settings a range of diagnostic tests and antibodies. Our pioneering product portfolio includes assays for underserved disease states such as NGAL for acute kidney injury. We sell our products in more than 80 countries through diverse sales channels and partners. BioPorto has its headquarters in Copenhagen, Denmark and is listed on the NASDAQ OMX Copenhagen stock Exchange.
